Dividends • 20/20 Biolabs

20/20 Biolabs, Inc., based in Rockville, Maryland, is a commercial-stage diagnostics company dedicated to improving health outcomes through early disease detection. The company leverages machine learning and advanced laboratory techniques to develop innovative testing solutions. Its primary focus is on its 'OneTest' platform, a multi-cancer screening tool that analyzes a panel of tumor biomarkers to help identify the risk of several types of cancer in their early, more treatable stages. In addition to cancer diagnostics, 20/20 Biolabs has expanded its portfolio to include rapid diagnostic tests and laboratory services, notably providing COVID-19 testing solutions and other respiratory panels. The company operates a CLIA-certified and CAP-accredited laboratory, ensuring high standards for its diagnostic offerings. By combining biological data with artificial intelligence, 20/20 Biolabs aims to provide clinicians and patients with actionable health insights, positioning itself at the intersection of biotechnology and digital health. The company's mission is to make early cancer detection more accessible and effective through the integration of data science and clinical diagnostics.

See below the complete and updated table with all dividends paid and declared history, etc